Sign in
Taking people in United StatesPhase 1

Tests saroglitazar in adults with liver scarring from cholestatic liver disease

Tests how the body handles saroglitazar in people with moderate liver impairment from cirrhosis.

Key facts

Who runs it
Zydus Therapeutics Inc.
Where
Indianapolis, United StatesSee the site
Trial code
Registry title
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Status
Recruiting
Phase
Phase 1
People taking part
6 people, planned
Started
5 Aug 2025
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Saroglitazar Magnesium 1 mg
Record updated
14 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cirrhosis (scarred liver) caused by cholestatic liver disease and moderately reduced liver function. It studies how the body handles saroglitazar magnesium 1 mg given on alternate days.

Age
18 to 80 years
Sex
Men and women
Disease stage
Cirrhosis due to cholestatic liver disease with moderate hepatic impairment, Child-Pugh Turcotte score 7 to 9
Earlier treatment
Must not have received another investigational drug within 30 days or 5 half-lives (whichever is longer) before saroglitazar. Must not have received blood products within 1 month of check-in.
Biomarker or test result
Alkaline phosphatase above the upper limit of normal; alanine aminotransferase/aspartate aminotransferase no more than 10 times the upper limit of normal; other blood values within set limits (neutrophils, platelets, hemoglobin, α-fetoprotein); body mass index 18.0 to 48.0 kg/m2

Main reasons for not taking part

  • Other causes of liver disease, such as fatty liver disease, autoimmune hepatitis or hepatitis B or C
  • HIV type 1 antibody positive
  • Pregnant or breastfeeding
  • Estimated glomerular filtration rate below 45 mL/min/1.73 m2
  • Cancer in the last 3 years (some skin and in situ cancers excepted)

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Male and/or female aged 18 to 80 years (both inclusive) at the time of signing the ICF
  • Body mass index within the range 18.0 to 48.0 kg/m2 (inclusive) at screening
  • Ability to swallow and retain oral medication
  • Subjects having documented history of hepatic impairment with cirrhosis due to cholestatic liver disease having Child-Pugh Turcotte score 7 to 9. If the hepatic impairment classification for the subject is not the same at screening and Day -1, enrolment of the subject into a hepatic category group will be at the discretion of the investigator
  • Laboratory test values must be clinically acceptable to the investigator and meet all the following parameters at screening:; Alkaline Phosphatase > upper limit of normal Alanine aminotransferase/Aspartate aminotransferase value ≤ 10 × upper limit of normal Absolute neutrophil count ≥ 750/mm3 Platelets ≥ 25,000/mm3 Hemoglobin ≥ 8 g/dL α-fetoprotein <50 ng/mL or 50-80 ng/mL with negative imaging study (Ultrasound [US], computed tomography scan [CT], Magnetic Resonance Imaging [MRI]). Imaging study that excluded presence of liver cancer (US in the preceding 6 months and CT or MRI in the preceding 1 year)
  • Must provide written informed consent and agree to comply with the trial protocol

Who cannot take part

  • Any major surgery within 3 months of screening
  • Human immunodeficiency virus type 1 antibody positive at screening
  • Any significant or unstable medical condition or other instability that would prevent the subject from participating in the study as determined by the investigator
  • History of malignancy of any type in the last 3 years of screening, with the exception of the following: in situ cervical or breast cancer or surgically excised non-melanoma skin cancers (i.e., basal cell or squamous cell carcinoma)
  • History of stomach or intestinal surgery or resection within 6 months of screening that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed)
  • The history of any significant drug allergy (such as anaphylaxis) deemed clinically relevant by the investigator
  • Active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment or symptoms of active infectious disease within 2 weeks of screening
  • Other known causes of liver disease, such as non-alcoholic steatohepatitis , alcoholic steatohepatitis, autoimmune hepatitis, or acute or chronic viral hepatitis (including Hepatitis B and C) as determined by the investigator and subject's medical records
  • Subjects who have had a change in hepatic disease status within 30 days of screening, as documented by the subject's medical history and deemed clinically significant by the investigator
  • Subjects having - History of gastrointestinal bleeding within 1 month of screening. Current functioning organ transplant. Evidence of severe ascites requiring frequent paracentesis in the opinion of the investigator
  • Receiving or has received any investigational drug within 30 days or 5 half-lives (whichever is longer), before receiving Saroglitazar Magnesium
  • Donation of blood or blood products within 3 months of screening
  • Estimated glomerular filtration rate (<45 mL/min/1.73 m2 by CKD-EPI 2021 formula at screening
  • Any individual with poor peripheral venous access
  • Receipt of blood products within 1 month of check in
  • Pregnancy-related exclusions, including:; Pregnant/lactating female (including positive pregnancy test at screening) Pregnancy should be avoided by male and female subjects either by true abstinence or the use of an acceptable effective contraceptive measures for the duration of the study and for at least 1 month after the end of the study treatment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Indianapolis, IndianaHospital not named in the registryContact: Mandy CruzTaking people

About the trial

What the trial wants to find out

Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease

The group in the trial

  • Saroglitazar Magnesium 1 mgTreatment being tested

    Saroglitazar Magnesium 1 mg tablet orally administered on alternate days in the morning before breakfast without food, for the duration of treatment (29 days)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, Open-label, Single Arm Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
Plain-language title
Tests saroglitazar in adults with liver scarring from cholestatic liver diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06825559, who can take part
Record updated
14 September 2026